A translational research study testing the biology of monocyte-derived dendritic cells and immune effector cells from subjects with advanced renal cell cancer currently treated with Sutent (Sunitinib) or Nexavar (Sorafenib)
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2007
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cancer
- Focus Pharmacodynamics
- 12 Apr 2007 New trial record.